title: Recanalization devices should be restricted to clinical trials: pro (kind of).
authors.affiliation: Department of Neurology, University of Erlangen, Schwabachanlage 6, Erlangen, Germany D-91054. peter.schellinger@uk-erlangen.de
authors.forename: Peter D
authors.initials: PD
authors.lastname: Schellinger
authors.forename: Werner
authors.initials: W
authors.lastname: Hacke
mesh_terms: D002404:Catheterization / Q000295:instrumentation / Q000379:methods; D002986:Clinical Trials as Topic / Q000295:instrumentation* / Q000379:methods*; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000473:pathology / Q000628:therapy; D015912:Thrombolytic Therapy / Q000295:instrumentation* / Q000379:methods*; D014654:Vascular Patency
chemical_list: D005343:Fibrinolytic Agents